Denileukin diftitox: a concise clinical review

Abstract

Denileukin diftitox (DAB₃₈₉IL-2; Ontak^®) is a novel recombinant fusion protein approved by the US Food and Drug Administration for the treatment of relapsed or refractory cutaneous T-cell lymphoma. It consists of fragments of diphtheria toxin linked to human interleukin-2 and works by targeting the high-affinity interleukin-2 receptor expressed on malignant cells. This article will review the clinical trials leading to the approval of denileukin diftitox for cutaneous T-cell lymphoma, and discuss the potential future role of this novel drug in patients with both malignant and nonmalignant diseases, including non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, solid tumors, psoriasis and graft-versus-host disease.

Keywords::

• cutaneous T-cell lymphoma
• DAB₃₈₉IL-2
• denileukin diftitox
• diphtheria toxin
• fusion protein
• Ontak^®